Exceptional disease control with neratinib monotherapy in HER2-positive advanced breast cancer: A case report
Human epidermal growth factor receptor 2 (HER2) represents a crucial drug target in breast cancer treatment. Currently, several agents that target HER2 are available, including monoclonal antibodies, antibody-drug conjugates, and tyrosine kinase inhibitors (TKIs). Despite major research efforts, no...
| Autores principales: | , , , , , , , |
|---|---|
| Formato: | Artículo |
| Lenguaje: | English |
| Publicado: |
Elsevier
2022-06-01
|
| Colección: | Current Problems in Cancer: Case Reports |
| Materias: | |
| Acceso en línea: | http://www.sciencedirect.com/science/article/pii/S266662192200031X |